CorMedix (CRMD) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
23 Jun, 2026Opening remarks and agenda
Meeting called to order virtually, with introductions of executive officers and board members.
Procedural matters and formal business to be conducted, with voting on eight proposals.
Shareholder proposals
Eight proposals presented: election of directors, executive compensation, auditor ratification, certificate of designation amendments, technical charter changes, preferred stock amendment process, exclusive forum designation, and officer liability limitation.
Overview of voting outcomes
All seven director nominees elected to the board.
Executive compensation for 2025 approved on a non-binding advisory basis.
Appointment of CBIZ CPAs as independent auditor for 2026 ratified.
Proposals on certificate of designation amendments, technical charter changes, preferred stock amendment process, exclusive forum designation, and officer liability limitation all failed to receive necessary votes.
Final voting results to be filed on Form 8-K with the SEC within four business days.
Latest events from CorMedix
- Q2 2026 revenue and earnings surged, led by DefenCath and Melinta, with raised guidance.CRMD
Q2 2026 - 2026 guidance reflects a transitional year as pipeline assets and new markets drive future growth.CRMD
44th Annual J.P. Morgan Healthcare Conference - Diversified portfolio, pipeline progress, and reimbursement shifts set stage for future growth.CRMD
Jefferies Global Healthcare Conference 2026 - Strong growth driven by DefenCath, REZZAYO, and pipeline expansion in institutional markets.CRMD
Corporate presentation - REZZAYO advances toward broader approval as DefenCath guidance and reimbursement outlook improve.CRMD
RBC Capital Markets Global Healthcare Conference 2026 - Diversified portfolio and robust pipeline drive growth, targeting major unmet needs in anti-infectives.CRMD
Investor Day 2026 - Q3 2025 net income hit $108.6M on strong sales and Melinta integration, with raised FY guidance.CRMD
Q3 2025 - DefenCath launch drove $11.5M Q3 revenue, strong margins, and expanded US dialysis access.CRMD
Q3 2024 - First profitable quarter: $39.1M revenue, $20.6M net income, H1 guidance at $70M.CRMD
Q1 2025